In last trading session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) saw 0.73 million shares changing hands with its beta currently measuring -1.23. Company’s recent per share price level of $7.74 trading at -$0.16 or -2.03% at ring of the bell on the day assigns it a market valuation of $784.47M. That closing price of DAWN’s stock is at a discount of -133.46% from its 52-week high price of $18.07 and is indicating a premium of 17.18% from its 52-week low price of $6.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.1 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.

For Day One Biopharmaceuticals Inc (DAWN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.43 in the current quarter.

Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information

Upright in the red during last session for losing -2.03%, in the last five days DAWN remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $7.74 price level, adding 2.15% to its value on the day. Day One Biopharmaceuticals Inc’s shares saw a change of -38.91% in year-to-date performance and have moved 13.16% in past 5-day. Day One Biopharmaceuticals Inc (NASDAQ:DAWN) showed a performance of -4.68% in past 30-days. Number of shares sold short was 17.48 million shares which calculate 12.56 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 40 to the stock, which implies a rise of 80.65% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -210.08% in reaching the projected high whereas dropping to the targeted low would mean a loss of -210.08% for stock’s current value.

Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts

This year revenue growth is estimated to rise 18.86% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 30.27M for the same. And 8 analysts are in estimates of company making revenue of 36.54M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.09% during past 5 years.

Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders

Insiders are in possession of 16.96% of company’s total shares while institution are holding 94.51 percent of that, with stock having share float percentage of 113.82%. Investors also watch the number of corporate investors in a company very closely, which is 94.51% institutions for Day One Biopharmaceuticals Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at DAWN for having 7.87 million shares of worth $108.47 million. And as of 2024-06-30, it was holding 9.0354 of the company’s outstanding shares.

The second largest institutional holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, which was holding about 6.43 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.3808 of outstanding shares, having a total worth of $88.61 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.24 shares of worth $17.3 million or 2.21% of the total outstanding shares. The later fund manager was in possession of 1.69 shares on Feb 28, 2025 , making its stake of worth around $13.1 million in the company or a holder of 1.67% of company’s stock.